Form 4: Lexeo Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Eric Adler, Chief Medical Officer of Lexeo Therapeutics, sold 585 shares of common stock on May 16, 2025, to cover tax obligations related to the release of restricted stock units.
Summary
- On May 16, 2025, Eric Adler, the Chief Medical Officer of Lexeo Therapeutics, sold 585 shares of common stock.
- The sale was executed at a price of $2.774 per share.
- This transaction was to cover tax obligations associated with the release of restricted stock units (RSUs).
- Following the transaction, Adler directly owns 67,681 shares, which includes 62,226 RSUs.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a small sale of shares by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of stock sale transaction |
| 05/20/2025 | Date of signature on the Form 4 filing |
Keywords
Lexeo Therapeutics, Eric Adler, Chief Medical Officer, stock sale, Form 4, RSUs, LXEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.